Introduction

Functional pancreatic sphincter of Oddi disorder (SOD) is classified under the Rome IV framework as category E3. It is defined by episodes of pancreatic-type pain (epigastric and/or left upper quadrant pain with specific characteristics) accompanied by documented transient elevations in serum amylase and/or lipase during pain episodes, in the absence of structural pancreatic duct pathology. This condition represents one of the most complex, debated, and clinically challenging entities in gastroenterology, sitting at the intersection of functional gastrointestinal disease, pancreaticobiliary pathology, and interventional endoscopy.

The sphincter of Oddi is a muscular valve at the junction of the common bile duct, the pancreatic duct, and the duodenum. It regulates the flow of bile and pancreatic juice into the duodenal lumen and prevents duodenal reflux into the ductal systems. When the pancreatic component of the sphincter is believed to dysfunction, impeding normal pancreatic duct drainage, the result can be recurrent episodes of pancreatic-type pain with or without biochemical evidence of pancreatic duct obstruction.

The concept of sphincter of Oddi disorder has undergone substantial evolution over the past several decades. Historical classification systems (particularly the Milwaukee classification) stratified patients based on a combination of symptoms, laboratory findings, imaging abnormalities, and sphincter of Oddi manometry results. The Rome IV criteria, published in 2016, represent the current international consensus framework and have shifted the diagnostic paradigm away from invasive manometry and toward a symptom-based, non-invasive approach. This shift was driven in large part by the landmark EPISOD trial, which demonstrated that endoscopic sphincterotomy did not outperform sham intervention for suspected biliary SOD in patients without objective evidence of obstruction, fundamentally changing the field's approach to these disorders.

Anatomy and Physiology of the Sphincter of Oddi

Understanding the anatomy and physiology of the sphincter of Oddi is essential for appreciating the pathophysiology and clinical presentation of pancreatic SOD.

Anatomy

The sphincter of Oddi is a complex muscular structure located at the junction where the common bile duct (CBD) and the main pancreatic duct (MPD, duct of Wirsung) enter the duodenum through the major duodenal papilla (ampulla of Vater). The sphincter has three functional components:

• Sphincter choledochus: Surrounds the intramural portion of the common bile duct.
• Sphincter pancreaticus: Surrounds the intramural portion of the main pancreatic duct.
• Sphincter ampullae (common sphincter): Surrounds the common channel (ampulla) where the bile and pancreatic ducts merge before opening into the duodenum.

The relative development and independence of these three components vary among individuals. In some patients, the biliary and pancreatic sphincters operate relatively independently; in others, they are more closely coupled. This anatomic variability may influence whether dysfunction manifests predominantly as biliary-type symptoms, pancreatic-type symptoms, or both.

The ductal anatomy also varies. Approximately 60% to 70% of individuals have a common channel where the CBD and MPD merge before exiting through the papilla. In others, the ducts may enter the duodenum separately or through a very short common channel. The presence and length of the common channel may be relevant to the pathophysiology of pancreatic SOD, as a long common channel may predispose to reflux of bile into the pancreatic duct if sphincter function is altered.

Physiology

The sphincter of Oddi maintains a tonic resting pressure (typically 10 to 35 mmHg above duodenal baseline) that prevents continuous drainage of bile and pancreatic juice into the duodenum and prevents duodenal reflux into the ductal systems. Superimposed on this tonic pressure are phasic contractions (rhythmic contractions occurring at a frequency of approximately 3 to 6 per minute) that propagate in an antegrade (toward the duodenum) direction, actively propelling bile and pancreatic juice into the intestinal lumen.

Sphincter relaxation is triggered by several physiological stimuli, most importantly cholecystokinin (CCK), which is released from duodenal I-cells in response to fat and protein in the duodenal lumen. CCK causes gallbladder contraction and simultaneous sphincter of Oddi relaxation, facilitating coordinated delivery of bile and pancreatic juice into the duodenum for digestion. Other hormones and neurotransmitters involved in sphincter regulation include secretin, vasoactive intestinal polypeptide (VIP), nitric oxide (NO), and substance P.

In functional pancreatic SOD, the pancreatic sphincter is hypothesized to dysfunction by either failing to relax appropriately in response to physiological stimuli or by exhibiting excessive tonic or phasic contractile activity, leading to impaired pancreatic duct drainage, transient pancreatic ductal hypertension, and pain.

Historical Context: The Milwaukee Classification and the EPISOD Trial

The Milwaukee Classification

Before Rome IV, the most widely used classification system for SOD was the Milwaukee classification, developed by Hogan and Geenen. This system categorized patients (primarily post-cholecystectomy patients with suspected biliary SOD) into three types based on a combination of clinical findings:

• Type I: Biliary-type pain with objective evidence of biliary obstruction, including a dilated common bile duct (>12 mm) on imaging AND elevated liver enzymes (AST, ALT, or alkaline phosphatase >2 times the upper limit of normal on two or more occasions during pain episodes).
• Type II: Biliary-type pain with one or two of the objective findings (dilated duct or elevated enzymes, but not both).
• Type III: Biliary-type pain without any objective evidence of obstruction (normal duct caliber, normal liver enzymes).

A parallel classification existed for pancreatic SOD, substituting pancreatic duct dilation and elevated amylase/lipase for the biliary parameters. Management was stratified by type: Type I patients were generally offered sphincterotomy based on clinical evidence alone, Type II patients were referred for sphincter of Oddi manometry (SOM) to guide therapy, and Type III patients were the most controversial group. The central question for Type III was whether manometry-guided sphincterotomy provided meaningful benefit.

The EPISOD Trial

The Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) trial, published in 2014, was a landmark multicenter, randomized, sham-controlled trial that evaluated biliary sphincterotomy versus sham procedure in patients with suspected biliary SOD Type III (post-cholecystectomy biliary-type pain without objective evidence of obstruction). All patients underwent SOM, and those with both elevated and normal sphincter pressures were randomized to sphincterotomy or sham.

The key finding was that sphincterotomy did not improve outcomes compared to sham in either subgroup (elevated or normal SOM pressures). This result fundamentally challenged the rationale for invasive manometry and sphincterotomy in SOD Type III and led to a paradigm shift. The EPISOD trial demonstrated that:

• Sphincter of Oddi manometry does not reliably identify patients who will benefit from sphincterotomy in the Type III population.
• Sphincterotomy provides no benefit over sham procedure in this group.
• Both groups (sphincterotomy and sham) showed similar improvement rates, suggesting a substantial placebo/sham effect.

While the EPISOD trial specifically addressed biliary SOD Type III, its implications extended to pancreatic SOD as well, reinforcing the need for caution with invasive interventions when objective evidence of obstruction is absent. The trial was one of the key influences on the Rome IV framework's approach to sphincter of Oddi disorders.

The Rome IV Shift

Rome IV absorbed the lessons of the EPISOD trial and moved away from the Milwaukee classification's heavy reliance on manometry. Under Rome IV, SOM is no longer considered a primary diagnostic tool for functional SOD. Instead, the diagnosis is based on clinical criteria (the pain pattern), non-invasive imaging (exclusion of structural pathology), and laboratory evidence (enzyme elevations during pain for pancreatic SOD). This shift represents a fundamental reorientation from an interventional, manometry-driven paradigm to a conservative, symptom-based, and exclusion-focused approach.

The Rome IV Diagnostic Criteria for Functional Pancreatic SOD (E3)

The Rome IV criteria for functional pancreatic sphincter of Oddi disorder require two components to be fully satisfied: the Rome IV pancreatic pain definition (7 criteria) and the SOD-specific criteria (2 criteria). All must be met.

Part 1: The Rome IV Pancreatic Pain Definition (7 Criteria)

The pancreatic pain definition parallels the biliary pain definition used in Rome IV categories E1 and E2, with one key difference: the anatomic location. Pancreatic-type pain is centered in the epigastrium and/or left upper quadrant, reflecting the visceral afferent pathways from the pancreas, whereas biliary pain is centered in the epigastrium and/or right upper quadrant.

1. Pain Located in the Epigastrium and/or Left Upper Quadrant

Pancreatic pain is characteristically located in the epigastric region and/or the left upper quadrant (LUQ). Radiation to the back, particularly the mid-back or left posterior region, is common and supportive. The epigastric localization is more frequent than isolated LUQ pain in many patients, as the pancreas sits in the retroperitoneum and its visceral afferents converge on thoracic spinal cord segments (T5-T9) that also receive somatic afferents from the epigastric dermatomes. Pain localized exclusively to the right upper quadrant is more consistent with biliary pain (categories E1/E2) than pancreatic pain.

2. Builds Up to a Steady Level

Like biliary pain, pancreatic pain builds progressively to a constant, steady plateau. It is not truly colicky (waxing and waning in waves). The steady-state character reflects visceral pain arising from ductal or parenchymal distension rather than from hollow organ peristalsis. Pain that fluctuates markedly in intensity or comes in brief waves is more suggestive of intestinal colic or other non-pancreatic etiologies.

3. Lasts 30 Minutes or Longer

Episodes persist for at least 30 minutes, and most genuine pancreatic pain episodes last 1 to several hours. Brief, fleeting episodes of upper abdominal discomfort lasting seconds to minutes are not consistent with the Rome IV pancreatic pain definition. Prolonged, unremitting pain (lasting more than 6 to 12 hours, particularly if escalating in severity) raises concern for acute pancreatitis and warrants urgent evaluation.

4. Occurs at Variable Intervals (Not Daily)

Pancreatic-type pain episodes recur at irregular, unpredictable intervals. Daily or continuous pain is not characteristic of functional pancreatic SOD and should prompt consideration of chronic pancreatitis, pancreatic malignancy, or non-pancreatic causes of chronic daily abdominal pain. The episodic, unpredictable nature of the pain reflects transient obstruction or spasm at the sphincter level rather than a fixed structural process.

5. Severe Enough to Interrupt Daily Activities or Lead to an Emergency Department Visit

The pain must be intense enough to disrupt normal activities or prompt emergency medical evaluation. This severity threshold distinguishes functional pancreatic SOD from mild, chronic, low-grade upper abdominal discomfort seen in functional dyspepsia and other conditions. Patients with functional pancreatic SOD often describe episodes that are incapacitating, frequently leading to emergency department visits with repeated imaging and laboratory testing.

6. Not Significantly Related to Bowel Movements (<20%)

The pain is not meaningfully relieved or exacerbated by defecation. This criterion distinguishes pancreatic-type pain from the abdominal pain of irritable bowel syndrome (IBS), which is, by definition, related to defecation. A patient whose epigastric or LUQ pain consistently improves with bowel movements is more likely to have IBS than pancreatic SOD.

7. Not Significantly Relieved by Postural Change or Acid Suppression (<20%)

Positional changes and acid-suppressive therapy do not provide meaningful relief. Pain that improves with leaning forward (a classic feature of pancreatic pain from chronic pancreatitis, but also seen in functional pancreatic SOD) may still be present, though the criterion specifically addresses relief from postural change or acid suppression in less than 20% of episodes. Pain that consistently responds to proton pump inhibitors (PPIs) or antacids is more suggestive of GERD or peptic ulcer disease.

Part 2: SOD-Specific Criteria (2 Criteria)

Once the pancreatic pain definition is satisfied, two additional criteria must be met:

1. Absence of Structural Pancreatic Duct Pathology

Appropriate imaging must demonstrate the absence of pancreatic duct stones, dominant strictures, mass lesions, or other structural findings that explain the symptoms. This is a critical exclusionary requirement because many organic conditions can produce pancreatic-type pain with enzyme elevations, and these must be thoroughly evaluated before applying a functional diagnosis.

Recommended imaging modalities include:

• Magnetic resonance cholangiopancreatography (MRCP): The preferred non-invasive modality for evaluating pancreatic and biliary ductal anatomy. MRCP can identify ductal dilation, stones, strictures, and anatomic variants (including pancreas divisum, which may be relevant to the differential diagnosis).
• Endoscopic ultrasound (EUS): Provides high-resolution imaging of the pancreatic parenchyma and duct, and can detect subtle findings missed by MRCP, including small stones, early chronic pancreatitis (using the Rosemont criteria), and ampullary lesions.
• CT scan: Useful for excluding pancreatic masses, calcifications (suggesting chronic pancreatitis), and peripancreatic pathology.
• Secretin-enhanced MRCP (sMRCP): Secretin stimulates pancreatic exocrine secretion and ductal filling, improving visualization of the pancreatic duct and potentially revealing subtle ductal abnormalities or impaired drainage. It can also provide a functional assessment of pancreatic duct compliance and emptying.

The absence of structural pathology on comprehensive imaging is essential. If imaging reveals stones, strictures, or masses, the diagnosis is the identified structural condition, not functional pancreatic SOD.

2. Elevated Serum Amylase and/or Lipase During Episodes of Pain

This is the defining biochemical criterion that distinguishes functional pancreatic SOD from other functional biliary and pancreatic disorders. During episodes of pain, serum amylase and/or lipase must be documented as elevated above the upper limit of normal. This transient enzyme elevation provides objective evidence that the pancreas is being affected during pain episodes, supporting the hypothesis that sphincter dysfunction is causing transient pancreatic ductal obstruction.

Several practical considerations apply:

• Timing of blood draws: Enzyme elevations may be transient, peaking within hours of symptom onset and normalizing within 24 to 48 hours. Patients must present for laboratory testing during or shortly after episodes. A delay of several days may result in normal values even if enzymes were elevated during the acute episode.
• Magnitude of elevation: Rome IV does not mandate a specific fold-rise above the upper limit of normal. Any documented elevation above the reference range during pain is considered positive. In clinical practice, elevations of 1.5 to 3 times the upper limit of normal are commonly observed in functional pancreatic SOD, though higher elevations may occur and should prompt evaluation for frank acute pancreatitis.
• Frequency of documentation: While Rome IV does not specify a minimum number of documented enzyme elevations, repeated documentation across multiple episodes strengthens the diagnostic confidence. A single isolated elevation may be coincidental or related to other causes (macroamylasemia, salivary amylase, renal insufficiency).
• Amylase versus lipase: Lipase is generally considered more specific for pancreatic pathology than amylase, as amylase can be elevated by salivary, renal, and other non-pancreatic sources. Ideally, both enzymes should be measured during episodes, though elevation of either is sufficient per Rome IV.

Supportive Criteria

Rome IV identifies several supportive features that are not required for diagnosis but that, when present, lend additional clinical confidence:

Recurrent Acute Pancreatitis

Some patients with functional pancreatic SOD present with recurrent episodes of acute pancreatitis (defined by two or more episodes meeting the Atlanta criteria: characteristic pain, enzyme elevation greater than 3 times the upper limit of normal, and/or imaging findings of acute pancreatitis). Recurrent acute pancreatitis in the absence of gallstones, significant alcohol use, hypertriglyceridemia, autoimmune markers, medications, or other identifiable causes raises the possibility of pancreatic sphincter dysfunction as the underlying mechanism. This presentation is sometimes called "idiopathic recurrent acute pancreatitis" (IRAP), and evaluation for pancreatic SOD is appropriate in this setting.

Main Pancreatic Duct Dilation Without Clear Structural Obstruction

Isolated dilation of the main pancreatic duct (greater than 3 to 4 mm in the body, depending on patient age) on imaging, in the absence of a visible stone, stricture, or mass causing obstruction, may support the hypothesis of impaired outflow at the sphincter level. However, MPD dilation can also occur with aging, chronic pancreatitis, and post-inflammatory changes, so this finding must be interpreted in clinical context.

Abnormal Pancreatic Sphincter Manometry (Historical)

Elevated basal sphincter pressure of the pancreatic sphincter segment (typically defined as greater than 40 mmHg above duodenal baseline) on sphincter of Oddi manometry was historically used to classify and guide treatment of pancreatic SOD. However, as discussed in the context of the EPISOD trial and the Rome IV paradigm shift, invasive manometry is rarely performed today and is not recommended as a routine diagnostic tool. When it is performed in selected cases at specialized centers, an elevated pressure is supportive but should not drive management decisions in isolation.

Epidemiology

The epidemiology of functional pancreatic SOD is poorly characterized compared to other functional gastrointestinal disorders. This is attributable to several factors: the diagnosis requires documentation of enzyme elevations during pain (which is logistically challenging), comprehensive pancreatic imaging is needed to exclude structural pathology, and the condition has been historically conflated with other forms of SOD and recurrent pancreatitis.

Among patients referred to tertiary pancreaticobiliary centers for evaluation of recurrent pancreatic-type pain or idiopathic recurrent acute pancreatitis, the proportion ultimately diagnosed with functional pancreatic SOD varies but likely represents a small minority. Studies of idiopathic recurrent acute pancreatitis have reported that 15% to 35% of cases may have sphincter of Oddi dysfunction as a contributing factor, though these estimates are based on manometric criteria that predate the Rome IV framework.

Functional pancreatic SOD appears to be more common in women than in men, consistent with the sex distribution of functional biliary disorders and gallbladder disease more broadly. The condition is predominantly diagnosed in post-cholecystectomy patients (since cholecystectomy is the most common antecedent to biliary and pancreatic sphincter evaluations), but it can also occur in patients with an intact gallbladder.

The age distribution is broad, but the condition is most commonly diagnosed in middle-aged adults (30 to 60 years). Psychological comorbidity (anxiety, depression, somatization) is prevalent, consistent with the gut-brain interaction model that underpins all Rome IV functional disorders.

Pathophysiology

The pathophysiology of functional pancreatic SOD remains incompletely understood, but several mechanisms have been proposed:

Sphincter Dyskinesia

The primary hypothesized mechanism is dysfunction of the pancreatic sphincter segment, leading to impaired relaxation, excessive tonic contraction, or paradoxical contraction during physiological stimulation. This sphincter "spasm" or "dyskinesia" is thought to impede normal pancreatic duct drainage, causing transient ductal hypertension, back-pressure on the pancreatic parenchyma, and pain. In severe cases, sustained ductal obstruction may precipitate frank acute pancreatitis.

Sphincter dyskinesia may involve abnormalities in the neural or hormonal pathways that regulate sphincter function. Impaired nitric oxide (NO) signaling, altered CCK receptor function, or imbalances in excitatory versus inhibitory neural input (from the enteric nervous system or vagal pathways) have been proposed as potential mechanisms.

Pancreatic Ductal Hypertension

When the pancreatic sphincter fails to relax appropriately, pancreatic secretions accumulate in the duct, leading to elevated intraductal pressure. This ductal hypertension distends the duct and the surrounding parenchyma, stimulating visceral afferent nerves and producing pain. The transient nature of the obstruction (as the sphincter eventually relaxes) explains the episodic character of the pain and the intermittent enzyme elevations.

In more severe cases, sustained ductal hypertension may lead to acinar cell injury, parenchymal edema, and biochemical acute pancreatitis. This provides the pathophysiological link between functional pancreatic SOD and idiopathic recurrent acute pancreatitis.

Visceral Hypersensitivity

As with other disorders of gut-brain interaction, visceral hypersensitivity may play a role in functional pancreatic SOD. Patients may have an enhanced perception of normal or mildly elevated ductal pressures, experiencing pain from physiological stimuli that would be imperceptible in non-sensitized individuals. This mechanism may be particularly relevant in patients who meet the pancreatic pain criteria but have only modest enzyme elevations, suggesting that the degree of ductal obstruction is mild but the patient's sensory threshold is low.

Peripheral sensitization of pancreatic visceral afferents may be triggered by prior episodes of acute pancreatitis, inflammation, or ischemia. Central sensitization, manifested as altered processing of visceral signals in the spinal cord and brain, may also contribute, particularly in patients with concurrent psychosocial comorbidity.

Post-Cholecystectomy Physiology

The majority of patients evaluated for functional pancreatic SOD have undergone prior cholecystectomy. Removal of the gallbladder alters the physiology of bile flow and may affect sphincter of Oddi function. Without the gallbladder as a bile reservoir, bile flows more continuously through the common bile duct and across the sphincter. This altered flow pattern may increase sphincter workload, change the hormonal milieu (altered CCK secretion patterns), or expose the sphincter to different pressures and flow dynamics. Whether these post-cholecystectomy physiological changes can directly cause sphincter dysfunction is debated, but the strong association between prior cholecystectomy and SOD presentations is well-documented.

Pancreas Divisum

Pancreas divisum is the most common congenital anatomic variant of the pancreatic duct, present in approximately 5% to 10% of the population. In pancreas divisum, the dorsal and ventral pancreatic ducts fail to fuse during embryological development, resulting in the majority of pancreatic secretions draining through the minor papilla (via the duct of Santorini) rather than the major papilla. If the minor papilla orifice is relatively small, this can create a functional obstruction to pancreatic drainage, mimicking sphincter dysfunction.

While pancreas divisum is a structural variant (not a functional disorder), it enters the differential diagnosis of functional pancreatic SOD and must be identified or excluded by MRCP or EUS. When pancreas divisum is present and symptomatic, the diagnosis and management differ from those of functional pancreatic SOD (minor papilla sphincterotomy or stenting may be considered).

Genetic Factors

Some patients with idiopathic recurrent acute pancreatitis and suspected pancreatic SOD carry genetic variants associated with pancreatitis susceptibility, including mutations in PRSS1 (hereditary pancreatitis), SPINK1 (serine protease inhibitor Kazal type 1), CFTR (cystic fibrosis transmembrane conductance regulator), and CTRC (chymotrypsin C). These genetic factors may predispose to pancreatitis through intrapancreatic trypsinogen activation or impaired protective mechanisms, and their presence should be considered in the evaluation, particularly in younger patients or those with a family history of pancreatitis.

Clinical Evaluation

The evaluation of a patient with suspected functional pancreatic SOD should be systematic, stepwise, and thorough, reflecting the seriousness of the differential diagnosis and the implications of the eventual management plan.

Step 1: Characterize the Pain Pattern

The clinician should systematically assess whether the patient's pain meets all seven Rome IV pancreatic pain criteria. Detailed questioning about location (epigastric and/or LUQ), character (steady plateau versus colicky), duration (at least 30 minutes), pattern (episodic at variable intervals, not daily), severity (severe enough to interrupt activities), relationship to bowel movements (not significantly related), and response to posture/acid suppression (not significantly relieved) is essential.

A pain diary maintained by the patient over several months can be invaluable for documenting the episodic nature, frequency, duration, and severity of attacks. The diary should also record any associated symptoms (nausea, vomiting, back radiation), concurrent laboratory testing, and dietary or situational triggers.

Step 2: Document Enzyme Elevations During Pain

Patients must be instructed to present for blood work during or immediately after pain episodes. Serum amylase and lipase should be drawn. Providing patients with standing laboratory orders and clear instructions to go to a laboratory or emergency department during an episode is a practical necessity, given the unpredictable timing of attacks.

Documentation of elevated amylase and/or lipase during at least one (preferably more) pain episode is required. Normal enzyme levels between episodes are expected and do not argue against the diagnosis.

Step 3: Comprehensive Pancreatic Imaging

• MRCP: Evaluates pancreatic and biliary ductal anatomy. Identifies ductal dilation, stones, strictures, and anatomic variants (including pancreas divisum).
• EUS: Provides high-resolution parenchymal and ductal imaging. Can detect early chronic pancreatitis, small stones, ampullary lesions, and pancreatic masses not visible on CT or MRCP.
• CT abdomen: Excludes pancreatic masses, calcifications, and peripancreatic pathology.
• Secretin-enhanced MRCP: May be considered to assess pancreatic duct compliance and emptying, and to detect subtle ductal abnormalities.

All imaging must be negative for structural pathology before functional pancreatic SOD can be diagnosed. If any structural abnormality is identified, the diagnosis shifts to the identified condition.

Step 4: Exclude Other Causes of Recurrent Pancreatitis

In patients presenting with recurrent acute pancreatitis as the predominant feature, a systematic evaluation for all known causes must be completed:

• Gallstones and microlithiasis: Transabdominal ultrasound, EUS, and/or bile microscopy.
• Alcohol: Detailed alcohol history.
• Hypertriglyceridemia: Fasting lipid panel, particularly triglycerides.
• Hypercalcemia: Serum calcium and parathyroid hormone.
• Autoimmune pancreatitis: IgG4 levels, pancreatic imaging patterns.
• Medications: Review of all medications for pancreatitis-associated drugs (azathioprine, valproic acid, GLP-1 receptor agonists, didanosine, pentamidine, and others).
• Genetic factors: PRSS1, SPINK1, CFTR, and CTRC testing in appropriate patients (young age, family history, recurrent idiopathic pancreatitis).
• Pancreas divisum: Identified on MRCP or EUS.
• Ampullary pathology: Ampullary adenoma or other periampullary lesions identified on EUS or side-viewing duodenoscopy.

Step 5: Consider Sphincter of Oddi Manometry (Selected Cases Only)

Sphincter of Oddi manometry (SOM) involves measurement of sphincter pressures via a catheter passed through the papilla during ERCP. An elevated basal sphincter pressure of the pancreatic sphincter segment (greater than 40 mmHg) was historically considered diagnostic of SOD.

Under the Rome IV framework, SOM is not recommended as a routine diagnostic tool. The EPISOD trial demonstrated that manometric findings did not predict response to sphincterotomy in the biliary SOD population, and similar concerns apply to the pancreatic sphincter. SOM carries a significant risk of procedure-related pancreatitis (reported rates of 10% to 30% when the pancreatic sphincter is instrumented), making its risk-benefit ratio unfavorable for routine use.

SOM may still be considered in highly selected cases at expert centers, typically in patients with recurrent acute pancreatitis and compelling clinical suspicion for pancreatic sphincter dysfunction, after all non-invasive evaluation has been exhausted and the multidisciplinary team has determined that manometric data would meaningfully change management.

Differential Diagnosis

The differential diagnosis for recurrent pancreatic-type pain with enzyme elevations is broad and requires systematic exclusion:

• Chronic pancreatitis: Progressive structural damage to the pancreas with calcifications, ductal irregularity, and exocrine/endocrine insufficiency. Imaging (CT, MRCP, EUS) and pancreatic function testing can distinguish chronic pancreatitis from functional pancreatic SOD.
• Recurrent acute pancreatitis from other causes: Gallstones/microlithiasis, alcohol, hypertriglyceridemia, hypercalcemia, autoimmune pancreatitis, medications, genetic susceptibility, and pancreas divisum (see Step 4 above).
• Pancreatic malignancy: Pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), and other pancreatic neoplasms may present with pain and enzyme abnormalities. Cross-sectional imaging and EUS are essential.
• Ampullary pathology: Ampullary adenoma, ampullary carcinoma, or impacted ampullary stone may obstruct pancreatic drainage.
• Functional biliary sphincter of Oddi disorder (E2): Biliary-type pain (RUQ/epigastric) in a post-cholecystectomy patient without structural biliary abnormality, distinguished from pancreatic SOD by the absence of pancreatic enzyme elevations and the RUQ predominance of pain.
• Functional gallbladder disorder (E1a): In patients with an intact gallbladder, biliary-type pain with normal labs during episodes. Distinguished from pancreatic SOD by location (RUQ versus LUQ) and absence of enzyme elevations.
• Functional dyspepsia: Epigastric pain or burning that may overlap with pancreatic-type pain but does not typically build to a severe, sustained plateau, does not cause enzyme elevations, and may respond to acid suppression.
• Peptic ulcer disease: Epigastric pain that may be relieved by antacids or food. Excluded by upper endoscopy.
• IBS: Abdominal pain related to defecation (criterion 6 helps distinguish).
• Cardiac disease: Atypical angina presenting as epigastric pain, particularly in patients with cardiovascular risk factors.
• Musculoskeletal pain: Thoracic spine pathology, costochondritis, and abdominal wall pain syndromes may mimic pancreatic pain.

Management Strategies

Management of functional pancreatic SOD has evolved significantly in the wake of the EPISOD trial and the Rome IV paradigm shift. The current approach emphasizes conservative and medical management, with invasive interventions reserved for carefully selected cases.

Conservative Management

• Patient education and reassurance: Explaining the diagnosis, its functional (non-malignant, non-progressive) nature, and the gut-brain interaction framework can reduce anxiety and improve coping. Patients with functional pancreatic SOD often have extensive prior medical evaluations, multiple emergency department visits, and significant psychological burden. Clear, empathetic communication about the diagnosis and prognosis is therapeutic in itself.
• Dietary modifications: Low-fat meals may reduce CCK-mediated sphincter and pancreatic stimulation. Small, frequent meals are generally better tolerated than large meals. Alcohol avoidance is recommended as alcohol can independently cause pancreatic inflammation and may worsen sphincter dysfunction.
• Avoidance of opioids: Opioids increase sphincter of Oddi tone and can worsen sphincter dysfunction. Their use should be minimized in patients with suspected or diagnosed pancreatic SOD. If analgesics are needed during acute episodes, non-opioid options (NSAIDs, acetaminophen) should be used when possible.

Pharmacological Therapy

• Calcium channel blockers: Nifedipine (10 to 20 mg sublingual or oral before meals) can relax smooth muscle, including the sphincter of Oddi, and has been used to reduce sphincter spasm and pain. Evidence is limited to small studies and case series, and the effect is often modest.
• Nitrates: Sublingual nitroglycerin or isosorbide dinitrate can cause sphincter relaxation through nitric oxide-mediated smooth muscle relaxation. Used for acute episodes in some centers, though systemic vasodilatory side effects (headache, hypotension) limit tolerability.
• Central neuromodulators: Low-dose tricyclic antidepressants (amitriptyline, nortriptyline, imipramine at 10 to 50 mg nightly) may reduce visceral hypersensitivity and central pain processing. These agents are increasingly recognized as important in the management of functional pancreatic SOD, consistent with the gut-brain interaction model. SSRIs or SNRIs (duloxetine, venlafaxine) may be considered when TCAs are not tolerated or when comorbid anxiety or depression warrants treatment.
• Gabapentinoids: Pregabalin or gabapentin may be used for visceral pain modulation, particularly in patients with a neuropathic component to their pain or when neuromodulators alone are insufficient.
• Pancreatic enzyme supplements: Supplemental pancreatic enzymes (pancrelipase) taken with meals can suppress CCK release through negative feedback (pancreatic enzymes in the duodenal lumen inhibit CCK secretion), theoretically reducing sphincter stimulation. Evidence for efficacy in functional pancreatic SOD is limited, but a therapeutic trial is low-risk and may benefit some patients.
• NSAIDs: Rectal indomethacin (100 mg) or diclofenac (100 mg) is established for preventing post-ERCP pancreatitis and has anti-inflammatory effects on the pancreas. Whether scheduled or as-needed oral NSAIDs benefit functional pancreatic SOD chronically is not well-studied, but they may provide symptomatic relief during acute episodes.

Psychological Therapies

Given the gut-brain interaction underpinnings of functional pancreatic SOD, psychological interventions may be valuable:

• Cognitive behavioral therapy (CBT): Addresses catastrophizing, pain-related hypervigilance, and maladaptive illness behaviors.
• Gut-directed hypnotherapy: Modulates visceral pain perception and has demonstrated efficacy in other functional GI disorders.
• Mindfulness-based stress reduction: May reduce the stress-mediated amplification of visceral pain signals.

Endoscopic Therapy (Selected Cases Only)

Endoscopic sphincterotomy (cutting the pancreatic sphincter to relieve obstruction) was formerly the primary treatment for pancreatic SOD, guided by manometric findings. In the post-EPISOD era, endoscopic therapy is approached with much greater caution:

• Pancreatic sphincterotomy: Involves endoscopic division of the pancreatic sphincter at the major papilla. Carries a significant risk of procedure-related pancreatitis (5% to 15% or higher). Reserved for patients with recurrent acute pancreatitis and strong objective evidence (documented enzyme elevations, possibly abnormal SOM) at expert centers. Rome IV does not endorse sphincterotomy as first-line therapy.
• Minor papilla sphincterotomy: Relevant when pancreas divisum is identified as a contributing factor, as the dominant drainage pathway is through the minor papilla. This is a structural variant rather than a functional SOD diagnosis.
• Temporary pancreatic duct stenting: Short-term placement of a pancreatic duct stent has been used diagnostically (to see if pain improves with ductal decompression) and therapeutically. However, pancreatic stent placement itself can cause ductal injury, stricture, and pancreatitis, and is not without risk. Stent trials are generally reserved for expert centers evaluating highly selected patients.

Surgical Options

Surgical transduodenal sphincteroplasty (surgical division of the sphincter of Oddi) is rarely performed in the modern era, having been largely replaced by endoscopic techniques. It may be considered in exceptional cases where endoscopic access to the papilla is not possible (e.g., altered post-surgical anatomy such as Roux-en-Y gastric bypass).

Using the Rome IV Functional Pancreatic SOD Calculator

The Rome IV Functional Pancreatic Sphincter of Oddi Disorder diagnostic criteria calculator is a clinical decision-support tool designed to systematically evaluate whether a patient's clinical findings meet the Rome IV criteria for functional pancreatic SOD (E3). The calculator is organized into two groups:

Pancreatic Pain Criteria (7 items):

1. Pain located in the epigastrium and/or left upper quadrant.
2. Pain builds up to a steady level.
3. Pain lasts 30 minutes or longer.
4. Pain occurs at variable intervals (not daily).
5. Pain is severe enough to interrupt daily activities or lead to an ED visit.
6. Pain is not significantly (<20%) related to bowel movements.
7. Pain is not significantly (<20%) relieved by postural change or acid suppression.

SOD-Specific Criteria (2 items):

1. Absence of pancreatic duct stones, stricture, tumor, or other structural pathology on appropriate imaging.
2. Elevated serum amylase and/or lipase documented during episodes of pain.

All 9 required elements must be affirmed for a positive result indicating that the Rome IV criteria for functional pancreatic SOD (E3) are met. The calculator provides three possible interpretive tiers:

• Criteria Met: All pancreatic pain and SOD-specific criteria are satisfied. The diagnosis of functional pancreatic SOD (E3) is supported.
• Pancreatic Pain Met, SOD Criteria Incomplete: The pain pattern is consistent with pancreatic-type pain, but the SOD-specific criteria (structural exclusion and/or enzyme elevation during pain) are not yet fulfilled. Further workup is recommended.
• Criteria Not Met: The pain pattern does not conform to the Rome IV pancreatic pain definition. Alternative diagnoses should be considered.

Supportive criteria (recurrent acute pancreatitis, main pancreatic duct dilation, abnormal manometry) are presented for reference but do not affect the required criteria assessment. This tool is intended for educational and clinical decision-support purposes and does not replace comprehensive clinical evaluation, appropriate imaging, laboratory documentation, or the judgment of a qualified healthcare provider.

Overlap with Other Rome IV Biliary and Pancreatic Disorders

Functional pancreatic SOD exists within the Rome IV category E spectrum of functional gallbladder and sphincter of Oddi disorders:

• E1a: Functional gallbladder disorder: Biliary pain in a patient with an intact gallbladder, no gallstones or structural abnormality, and normal liver/pancreatic enzymes during pain. Distinguished from pancreatic SOD by the absence of enzyme elevations and by RUQ (rather than LUQ) pain predominance.
• E1b: Functional biliary sphincter of Oddi disorder: Biliary-type pain in a post-cholecystectomy patient without structural biliary abnormality. Distinguished from pancreatic SOD by the biliary (RUQ/epigastric) location of pain, elevated liver enzymes (rather than pancreatic enzymes) during episodes, and absence of pancreatic enzyme elevations. Some patients may have both biliary and pancreatic sphincter dysfunction, presenting with features of both E1b and E3.
• E3: Functional pancreatic SOD: The subject of this article. Pancreatic-type pain (epigastric/LUQ) with elevated pancreatic enzymes during episodes and no structural pancreatic pathology.

Overlap between biliary and pancreatic sphincter dysfunction is recognized. Some patients may exhibit features of both biliary and pancreatic SOD, with enzyme patterns that include both transient liver enzyme and pancreatic enzyme elevations during episodes. The anatomic proximity and functional interdependence of the biliary and pancreatic sphincter segments make such overlap physiologically plausible.

Functional pancreatic SOD may also overlap with functional dyspepsia (B1), particularly the epigastric pain syndrome (EPS) subtype, which features bothersome epigastric pain. The distinguishing features are the severity and character of the pain (steady, severe, lasting 30+ minutes, interrupting activities, and not responding to acid suppression in pancreatic SOD), the presence of enzyme elevations, and the episodic (not daily) pattern. Some patients may meet criteria for both conditions, and management may need to address overlapping mechanisms.

The Role of ERCP in the Modern Era

Endoscopic retrograde cholangiopancreatography (ERCP) once occupied a central role in both the diagnosis and treatment of SOD. Under the Milwaukee classification, ERCP with sphincter of Oddi manometry was the definitive diagnostic procedure, and therapeutic sphincterotomy was performed during the same session if elevated pressures were found.

In the post-EPISOD, Rome IV era, the role of ERCP in functional SOD has been dramatically curtailed. ERCP carries a significant risk of complications, most importantly post-ERCP pancreatitis (overall risk 5% to 10%, but considerably higher when the pancreatic sphincter is manipulated or instrumented, up to 15% to 30% in some series). Other risks include perforation, bleeding, cholangitis, and adverse reactions to sedation.

Current consensus holds that ERCP should be reserved for therapeutic interventions in patients with confirmed structural pathology (e.g., choledocholithiasis, pancreatic duct stones, ampullary pathology) and should not be performed primarily for diagnostic purposes (manometry) in the functional SOD population. When ERCP is performed in selected patients with suspected pancreatic SOD (e.g., for therapeutic pancreatic sphincterotomy in the setting of recurrent acute pancreatitis), aggressive prophylactic measures against post-ERCP pancreatitis should be employed, including rectal indomethacin and prophylactic pancreatic duct stent placement.

Prognosis and Long-Term Outlook

The long-term prognosis of functional pancreatic SOD is variable and depends on several factors, including the severity and frequency of episodes, the presence or absence of recurrent acute pancreatitis, the patient's psychological profile, and the management approach.

Some patients experience a gradual reduction in episode frequency and severity over time, particularly with effective medical management and psychological support. Others have a chronic, relapsing course that significantly impairs quality of life. Patients with recurrent acute pancreatitis as a manifestation of pancreatic SOD are at theoretical risk of developing chronic pancreatitis over time if repeated inflammatory insults cause cumulative parenchymal damage, though this progression is not inevitable.

Functional pancreatic SOD does not carry an inherent increased risk of pancreatic malignancy. Reassurance on this point is important for patients who may be anxious about the significance of their symptoms and the recurrent pancreatic enzyme elevations.

Quality of life is often substantially impaired, driven by severe episodic pain, frequent emergency department visits, the unpredictability of episodes, and the psychological burden of a chronic pain condition. A comprehensive management approach that addresses biological mechanisms (medical therapy, avoidance of sphincter-stimulating agents), psychological factors (neuromodulators, psychotherapy), and social dimensions (functional impairment, disability) offers the best prospect for meaningful improvement.

Long-term follow-up with a gastroenterologist experienced in pancreaticobiliary disorders is recommended. Periodic reassessment of the diagnosis is appropriate, as some patients initially classified as having functional pancreatic SOD may develop new imaging or laboratory findings over time that redirect the diagnosis toward an organic condition requiring different management.